genotypeguided

Genotypeguided refers to medical decisions informed by an individual’s genetic information, especially for pharmacotherapy. It aims to tailor drug choice and dosing to improve safety and effectiveness and is a key element of precision medicine. The practice is distinct from the broader field of pharmacogenomics, which studies how genetic variation influences drug response.

In clinical use, genotypeguided strategies include adjusting warfarin dosing using CYP2C9 and VKORC1 genotypes, and dosing thiopurines based on TPMT status. Additional examples are testing for DPYD variants to limit fluoropyrimidine toxicity and selecting therapies or doses based on HLA or other pharmacogenetic markers to prevent serious adverse events. Organizations like CPIC provide guidelines that translate genotypes into dosing recommendations, and some genetic information is now integrated into drug labeling and electronic health record decision support.

Evidence for genotypeguided care varies by drug and context. Some approaches have demonstrated reduced adverse events and improved efficacy in controlled studies, while others show more modest or inconsistent benefits. Adoption is influenced by test availability, turnaround time, cost, and the ability to incorporate results into clinical workflows.

Challenges include ensuring equitable access to testing, protecting genetic privacy, and educating clinicians. Ongoing research seeks to expand gene–drug knowledge, confirm clinical utility across diverse populations, and streamline implementation through point‑of‑care testing and embedding decision support in health systems.